



## Clinical trial results:

### Safety and tolerability of 68Ga-DOTATOC for injection in patients with proven gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs)

#### Summary

EudraCT number	2014-002741-21
Trial protocol	GB
Global end of trial date	27 June 2016

#### Results information

Result version number	v1 (current)
This version publication date	04 June 2020
First version publication date	04 June 2020

#### Trial information

##### Trial identification

Sponsor protocol code	AAA-Ga-TOC-EU-01
-----------------------	------------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Advanced Accelerator Applications SA
Sponsor organisation address	20 rue Diesel, Saint-Genis-Pouilly, France, 01630
Public contact	Novartis Clinical Disclosure Office, Advanced Accelerator Applications SA, +41 613241111 , novartis.email@novartis.com
Scientific contact	Novartis Clinical Disclosure Office, Advanced Accelerator Applications SA, +41 613241111 , novartis.email@novartis.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

Analysis stage	Final
Date of interim/final analysis	27 June 2016
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	27 June 2016
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

Main objective of the trial:

The main objective of the study was to assess the safety and tolerability of a single administration of dose of 2 MBq/Kg  $\pm$  10% (range 100-200 MBq) of the kit for preparation of 68Ga-DOTATOC for injection (a radioactive diagnostic drug) in subjects with proven gastro-entero-pancreatic neuroendocrine tumors.

Protection of trial subjects:

The study was conducted in compliance with the ethical principles of the "Declaration of Helsinki" and with the principles of Good Clinical Practice as outlined in the International Conference for Harmonization (ICH) tripartite guideline.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	29 June 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects****Subjects enrolled per country**

Country: Number of subjects enrolled	United Kingdom: 20
Worldwide total number of subjects	20
EEA total number of subjects	20

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	12
From 65 to 84 years	8
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

This study was conducted at two centers in United Kingdom from 29-June-2015 (first subject enrolled) to 27-June-2016 (last subject last visit).

### Pre-assignment

Screening details:

Twenty subjects were enrolled in the study. All enrolled subjects completed the study and were administered with 68Ga-DOTATOC injected intravenously for the purpose of medical imaging.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	68Ga-DOTATOC
-----------	--------------

Arm description:

Subjects received a single dose of 2 MBq/kg +/- 10%, but not less than 100 MBq and not more than 200 MBq, of 68Ga-DOTATOC intravenously (IV).

Arm type	Experimental
Investigational medicinal product name	DOTA0-Tyr3-Octreotide
Investigational medicinal product code	
Other name	68Ga-DOTATOC
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received a single dose of 2 MBq/kg +/- 10% of IV 68Ga-DOTATOC.

<b>Number of subjects in period 1</b>	68Ga-DOTATOC
Started	20
Completed	20

## Baseline characteristics

### Reporting groups

Reporting group title	Overall Study
-----------------------	---------------

Reporting group description: -

Reporting group values	Overall Study	Total	
Number of subjects	20	20	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	12	12	
From 65-84 years	8	8	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	6	6	
Male	14	14	
Ethnicity			
Units: Subjects			
Caucasian	18	18	
Asian	1	1	
Black	1	1	

## End points

### End points reporting groups

Reporting group title	68Ga-DOTATOC
Reporting group description:	
Subjects received a single dose of 2 MBq/kg +/- 10%, but not less than 100 MBq and not more than 200 MBq, of 68Ga-DOTATOC intravenously (IV).	

### Primary: Number of Subjects with Adverse Events (AEs), Serious Adverse events (SAEs) and Death

End point title	Number of Subjects with Adverse Events (AEs), Serious Adverse events (SAEs) and Death <sup>[1]</sup>
-----------------	--

End point description:

AE was defined as any untoward medical occurrence in a clinical trial subject administered medicinal product and which does not necessarily have causal relationship with investigational product (IP). An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an IP, contrast media or drugs administered during the imaging tests, whether or not considered related to the IP. SAE is any untoward medical occurrence or effect that at any dose: results in death, is life-threatening, requires hospitalization, or prolongation of existing inpatient's hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect. This analysis was performed in safety set (SS). SS consisted of all subjects who took at least one dose of study medication.

End point type	Primary
----------------	---------

End point timeframe:

From start of the study up to follow up (Day 28)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics was planned for this endpoint.

End point values	68Ga-DOTATOC			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: number of subjects				
Adverse events (AEs)	12			
Serious Adverse events (SAEs)	0			
Death	0			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From start of study up to follow up (Day 28)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.1
--------------------	------

### Reporting groups

Reporting group title	68Ga-DOTATOC
-----------------------	--------------

Reporting group description:

Subjects received a single dose of 2 MBq/kg +/- 10%, but not less than 100 MBq and not more than 200 MBq, of 68Ga-DOTATOC intravenously (IV).

Serious adverse events	68Ga-DOTATOC		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 20 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	68Ga-DOTATOC		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	12 / 20 (60.00%)		
Nervous system disorders			
Headache			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Paraesthesia			
subjects affected / exposed	1 / 20 (5.00%)		
occurrences (all)	1		
General disorders and administration site conditions			
Flushing			
subjects affected / exposed	2 / 20 (10.00%)		
occurrences (all)	2		
Influenza like illness			

subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Eye disorders Eye irritation subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Gastrointestinal disorders Abdominal discomfort subjects affected / exposed occurrences (all)  Abdominal pain subjects affected / exposed occurrences (all)  Diarrhoea subjects affected / exposed occurrences (all)  Dysgeusia subjects affected / exposed occurrences (all)  Nausea subjects affected / exposed occurrences (all)  Pancreatic insufficiency subjects affected / exposed occurrences (all)  Proctalgia subjects affected / exposed occurrences (all)  Vomiting subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1  3 / 20 (15.00%) 3  4 / 20 (20.00%) 4  1 / 20 (5.00%) 1  2 / 20 (10.00%) 2  1 / 20 (5.00%) 1  1 / 20 (5.00%) 1  1 / 20 (5.00%) 1		
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all)  Rhinorrhoea	1 / 20 (5.00%) 1		

subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Psychiatric disorders Lethargy subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2		
Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1		



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 October 2014	Protocol amendment due to MHRA and EC comments. Initial version 1.0 was never applicable on-site.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Novartis acquired Advanced Accelerator Applications SA.

Notes: